Yüklüyor......
表皮生长因子受体突变细胞系H1650耐药机制探讨
BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor (EGFR) overexpression and mutations were existed in more than 40% of the lung cancer, and it's the one of molecular targets in clinical treatment. But the EGFR tyrosine kinase inhibitors (TKI)-resistance is becoming a challenging clinic...
Kaydedildi:
| Yayımlandı: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
中国肺癌杂志编辑部
2012
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6000043/ https://ncbi.nlm.nih.gov/pubmed/23249714 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2012.12.02 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|